-
Je něco špatně v tomto záznamu ?
Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants
Majerová-Uhlíková T, Dantuma NP, Lindsten K, Masucci MG, Konvalinka J.
Jazyk angličtina Země Nizozemsko
Typ dokumentu srovnávací studie
Grantová podpora
NR8571
MZ0
CEP - Centrální evidence projektů
- MeSH
- biotest metody MeSH
- fenotyp MeSH
- financování organizované MeSH
- fluorescenční mikroskopie MeSH
- fluorometrie MeSH
- HeLa buňky MeSH
- HIV-proteasa genetika metabolismus účinky léků MeSH
- hodnotící studie jako téma MeSH
- inhibitory HIV-proteasy farmakologie MeSH
- kinetika MeSH
- klonování DNA MeSH
- lidé MeSH
- monoklonální protilátky metabolismus MeSH
- mutace MeSH
- plazmidy MeSH
- průtoková cytometrie MeSH
- rekombinantní fúzní proteiny metabolismus MeSH
- reportérové geny MeSH
- transfekce MeSH
- virová léková rezistence MeSH
- virové geny MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- western blotting MeSH
- zelené fluorescenční proteiny metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- srovnávací studie MeSH
BACKGROUND: The introduction of HIV proteinase inhibitors (PIs) as anti-AIDS drugs resulted in decreased mortality and prolonged life expectancy of HIV-positive patients. However, rapid selection of drug-resistant HIV variants is a common complication in patients undergoing highly active anti-retroviral therapy (HAART). Thus, monitoring of clinical resistance development is indispensable for rational pharmacotherapy. OBJECTIVE: We present a non-infectious cell-based assay for drug resistance quantification of HIV proteinase (PR) - an important target of HAART. STUDY DESIGN: Previously, we showed [Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 2001;45:2616-22] that the expression of a fusion protein (GFP-PR), comprised of HIV-1 proteinase wild-type artificial precursor (PR) and green fluorescent protein (GFP), in transiently transfected tissue culture cells depends on the presence of PR-specific inhibitors (PIs). Here we show that in the GFP-PR reporter the HIV wild-type PR can be replaced by a drug-resistant HIV PR mutant, yielding a simple and biologically relevant tool for the quantitative analysis of drug-resistant HIV PR mutants susceptibility to HIV proteinase inhibitors. RESULTS: We cloned a set of GFP-PR reporters, some of which possess a simple, well-defined drug-resistant PR mutant (G48V L90M, V82A, A71V V82T I84V, D30N, K45I); another four complex PR mutants were obtained from patients undergoing HAART. The results were compared with genotyping and enzyme kinetics data. Furthermore, we designed a single inhibitor concentration experiment setup for easy evaluation of drug resistance profiles for mutants of interest. The resistance profiles clearly demonstrate the importance of succession of individual drugs during the treatment for drug resistance development. CONCLUSION: We show that the GFP-PR assay might serve as a non-infectious, rapid, cheap, and reliable alternative to the currently used phenotypic assays.
Citace poskytuje Crossref.org
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07521927
- 003
- CZ-PrNML
- 005
- 20131014125828.0
- 008
- 090423s2006 ne e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.jcv.2006.01.014 $2 doi
- 035 __
- $a (PubMed)16527535
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Majerová, Taťána $7 xx0157008
- 245 10
- $a Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants / $c Majerová-Uhlíková T, Dantuma NP, Lindsten K, Masucci MG, Konvalinka J.
- 314 __
- $a Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo 2, 166 10 Praha 6, Czech Republic
- 520 9_
- $a BACKGROUND: The introduction of HIV proteinase inhibitors (PIs) as anti-AIDS drugs resulted in decreased mortality and prolonged life expectancy of HIV-positive patients. However, rapid selection of drug-resistant HIV variants is a common complication in patients undergoing highly active anti-retroviral therapy (HAART). Thus, monitoring of clinical resistance development is indispensable for rational pharmacotherapy. OBJECTIVE: We present a non-infectious cell-based assay for drug resistance quantification of HIV proteinase (PR) - an important target of HAART. STUDY DESIGN: Previously, we showed [Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 2001;45:2616-22] that the expression of a fusion protein (GFP-PR), comprised of HIV-1 proteinase wild-type artificial precursor (PR) and green fluorescent protein (GFP), in transiently transfected tissue culture cells depends on the presence of PR-specific inhibitors (PIs). Here we show that in the GFP-PR reporter the HIV wild-type PR can be replaced by a drug-resistant HIV PR mutant, yielding a simple and biologically relevant tool for the quantitative analysis of drug-resistant HIV PR mutants susceptibility to HIV proteinase inhibitors. RESULTS: We cloned a set of GFP-PR reporters, some of which possess a simple, well-defined drug-resistant PR mutant (G48V L90M, V82A, A71V V82T I84V, D30N, K45I); another four complex PR mutants were obtained from patients undergoing HAART. The results were compared with genotyping and enzyme kinetics data. Furthermore, we designed a single inhibitor concentration experiment setup for easy evaluation of drug resistance profiles for mutants of interest. The resistance profiles clearly demonstrate the importance of succession of individual drugs during the treatment for drug resistance development. CONCLUSION: We show that the GFP-PR assay might serve as a non-infectious, rapid, cheap, and reliable alternative to the currently used phenotypic assays.
- 650 _2
- $a monoklonální protilátky $x metabolismus $7 D000911
- 650 _2
- $a biotest $x metody $7 D001681
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a klonování DNA $7 D003001
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a virová léková rezistence $7 D024882
- 650 _2
- $a hodnotící studie jako téma $7 D005069
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a fluorometrie $7 D005470
- 650 _2
- $a reportérové geny $7 D017930
- 650 _2
- $a virové geny $7 D005814
- 650 _2
- $a zelené fluorescenční proteiny $x metabolismus $7 D049452
- 650 _2
- $a HIV-proteasa $x genetika $x metabolismus $x účinky léků $7 D016333
- 650 _2
- $a inhibitory HIV-proteasy $x farmakologie $7 D017320
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a fluorescenční mikroskopie $7 D008856
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a plazmidy $7 D010957
- 650 _2
- $a rekombinantní fúzní proteiny $x metabolismus $7 D011993
- 650 _2
- $a transfekce $7 D014162
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Dantuma, Nico P.
- 700 1_
- $a Lindsten, Kristina
- 700 1_
- $a Masucci, Maria G.
- 700 1_
- $a Konvalinka, Jan, $d 1963- $7 mzk2004208597
- 773 0_
- $w MED00005010 $t Journal of clinical virology $g Roč. 36, č. 1 (2006), s. 50-59 $x 1386-6532
- 910 __
- $a ABA008 $b x $y 9 $z 0
- 990 __
- $a 20090312170439 $b ABA008
- 991 __
- $a 20131014130354 $b ABA008
- 999 __
- $a ok $b bmc $g 645016 $s 497932
- BAS __
- $a 3
- BMC __
- $a 2006 $b 36 $c 1 $d 50-59 $i 1386-6532 $m Journal of clinical virology $x MED00005010
- GRA __
- $a NR8571 $p MZ0
- LZP __
- $a 2009-B1/vtme